Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Canadian Morphea Registry (C-MORE): Characterizing the landscape of morphea in Canada and elucidating predictors of severe disease
FY 2022-23
Summary
Morphea, i.e., localized scleroderma (LS), is a chronic relapsing autoimmune fibrosing skin disease affecting ~75,000 Canadians. It is thought to be environmentally triggered in a genetically predisposed host. While not life-threatening, LS is physically/emotionally/cosmetically debilitating, with a high risk of extracutaneous involvement/pain/disfigurement/disability in severe forms. Many clinical/research gaps exist in LS as most current knowledge is based on only 2 single-center registries (Morphea in Adults and Children, Texas/National Registry for Childhood-Onset Scleroderma, Pittsburgh). Thus, studies are often limited by small numbers, unequal ethnocultural representation, retrospective data collection, and use of unvalidated classifications. Large registry data with heterogenous LS patients with age/sex/gender/ethnic representation is needed to study LS’ cutaneous/extracutaneous damage and health-related quality of life (HRQoL). We created the first national LS patient’s registry C-MORE comprised of 36 multidisciplinary physicians across 17 academic sites to study LS in Canada. Using patient-directed questionnaires, we will 1) characterize demographics (age/sex/gender/race), comorbidities (autoimmunity/cancer/antibodies) and extracutaneous manifestations (ocular/dental/neurologic/musculoskeletal) of adult/pediatric LS patients in Canada; 2) investigate factors associated with higher risk of extracutaneous disease; 3) assess LS’ impact on HRQOL/productivity/mental health. To our knowledge, C-MORE will be the 1st national registry and rapidly the largest LS cohort worldwide. This puts us in a unique position to advance LS research and help instruct clinicians on which patients are at higher risk of complications and should be followed/investigated more thoroughly.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486415
Name
Ghazal Stephanie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Canadian Morphea Registry (C-MORE): Characterizing the landscape of morphea in Canada and elucidating predictors of severe disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Auto-Immune Disease; Connective Tissue Disease; Dermatology; Epidemiology; Localized Scleroderma; Morphea; Registry; Skin
Abstract
Morphea, i.e., localized scleroderma (LS), is a chronic relapsing autoimmune fibrosing skin disease affecting ~75,000 Canadians. It is thought to be environmentally triggered in a genetically predisposed host. While not life-threatening, LS is physically/emotionally/cosmetically debilitating, with a high risk of extracutaneous involvement/pain/disfigurement/disability in severe forms. Many clinical/research gaps exist in LS as most current knowledge is based on only 2 single-center registries (Morphea in Adults and Children, Texas/National Registry for Childhood-Onset Scleroderma, Pittsburgh). Thus, studies are often limited by small numbers, unequal ethnocultural representation, retrospective data collection, and use of unvalidated classifications. Large registry data with heterogenous LS patients with age/sex/gender/ethnic representation is needed to study LS’ cutaneous/extracutaneous damage and health-related quality of life (HRQoL). We created the first national LS patient’s registry C-MORE comprised of 36 multidisciplinary physicians across 17 academic sites to study LS in Canada. Using patient-directed questionnaires, we will 1) characterize demographics (age/sex/gender/race), comorbidities (autoimmunity/cancer/antibodies) and extracutaneous manifestations (ocular/dental/neurologic/musculoskeletal) of adult/pediatric LS patients in Canada; 2) investigate factors associated with higher risk of extracutaneous disease; 3) assess LS’ impact on HRQOL/productivity/mental health. To our knowledge, C-MORE will be the 1st national registry and rapidly the largest LS cohort worldwide. This puts us in a unique position to advance LS research and help instruct clinicians on which patients are at higher risk of complications and should be followed/investigated more thoroughly.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ghazal, Stephanie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~